Interferon alfacon-1

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 03.04.2022

Dieser Artikel auf Deutsch

Synonym(s)

Interferon alphacon-1

Definition
This section has been translated automatically.

Non-naturally occurring, synthetic, recombinantly produced interferon-alfa derivative derived from the consensus sequence of different interferon alfa variants (CIFN = consensus interferon).

Indication
This section has been translated automatically.

Histologically confirmed chronic hepatitis in patients > 18 LJ in whom serum markers for hepatitis C virus (HCV) infection are present (e.g. patients with elevated serum transaminase levels without liver decompensation).

Limited indication
This section has been translated automatically.

Pat. < 18 LJ (insufficient data!).

Dosage and method of use
This section has been translated automatically.

Adults: 3 times/week 9 μg s.c. as single injection. Between 2 consecutive doses should preferably be 48 hours.

Undesirable effects
This section has been translated automatically.

Frequently flu-like general symptoms (fever, fatigue, chills, headaches, myalgia, sweating), reactions at the injection site (erythema)

Contraindication
This section has been translated automatically.

Serious heart disease in general, epilepsy, severe psychiatric disorders (depression, suicidal tendencies), severe kidney or liver disease, chronic hepatitis in patients treated with immunosuppressive drugs or who have recently been treated (except short-term therapy with glucocorticoids).

Preparations
This section has been translated automatically.

Inferax

Note(s)
This section has been translated automatically.

Remember! If a permanent or recurrent ADR develops after appropriate adjustment of the dose, or if the condition worsens, discontinue treatment.

Authors

Last updated on: 03.04.2022